<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab7">
 <label>Table 7</label>
 <caption>
  <p>Empirical treatment recommendations for suspected bacterial meningitis</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="6">Initial treatment recommendations*</th>
   </tr>
   <tr>
    <th> CMG</th>
    <th>3rd-generation cephalosporin (ceftriaxone
     <sup>^</sup> or cefotaxime)
    </th>
    <th>3rd generation-cephalosporin (ceftriaxone
     <sup>^</sup> or cefotaxime) plus a penicillin (amoxicillin, ampicillin or penicillin)
    </th>
    <th>Aminoglycoside (gentamicin) plus a penicillin (amoxicillin or ampicillin)</th>
    <th>Add: glycopeptide (vancomycin)</th>
    <th>Add: corticosteroids (before or with first dose of antibiotics)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td> EFNS Europe</td>
    <td>P, A</td>
    <td>E</td>
    <td/>
    <td>Older children and adults**</td>
    <td>Yes</td>
   </tr>
   <tr>
    <td> ESCMID Europe</td>
    <td>P, A</td>
    <td>N, A &gt; 50 years, or if risk factor for 
     <italic>L. monocytogenes</italic>
    </td>
    <td>N</td>
    <td>**,
     <sup>^</sup>
    </td>
    <td>Yes
     <sup>^</sup> up to 4 h post-antibiotics
    </td>
   </tr>
   <tr>
    <td> DSI Denmark</td>
    <td>A</td>
    <td>A if risk of 
     <italic>L. monocytogenes</italic>
    </td>
    <td/>
    <td/>
    <td>Yes</td>
   </tr>
   <tr>
    <td> SPILF France</td>
    <td>P, A</td>
    <td>P, A if suspected L. monocytogenes°</td>
    <td/>
    <td>If S. pneumoniae</td>
    <td>Yes
     <sup>″</sup>
    </td>
   </tr>
   <tr>
    <td> DGN: BM Germany</td>
    <td>A</td>
    <td>A</td>
    <td/>
    <td>A**</td>
    <td>Yes</td>
   </tr>
   <tr>
    <td> HPSC Ireland</td>
    <td>P &gt; 2 m, A</td>
    <td>N, P &lt; 2 months</td>
    <td>N, P &lt; 2 months</td>
    <td>**,
     <sup>^</sup>
    </td>
    <td>Yes up to 24 h post-antibiotics</td>
   </tr>
   <tr>
    <td> NVN Netherlands</td>
    <td>P, A</td>
    <td>N, A</td>
    <td/>
    <td/>
    <td>Yes</td>
   </tr>
   <tr>
    <td> MHSSE
     <sup>#</sup> Spain
    </td>
    <td>P</td>
    <td/>
    <td/>
    <td/>
    <td>Yes</td>
   </tr>
   <tr>
    <td> NICE UK</td>
    <td>P &gt; 3 m</td>
    <td>N, P &lt; 3 months</td>
    <td/>
    <td>If travel outside of the UK</td>
    <td>Yes
     <sup>^^</sup> up to 12 h post-antibiotics
    </td>
   </tr>
   <tr>
    <td> UKJSS UK</td>
    <td>A</td>
    <td>A &gt; 60 years</td>
    <td/>
    <td>Pending travel history</td>
    <td>Yes up to 12 h post-antibiotics</td>
   </tr>
   <tr>
    <td> SIGN
     <sup>#</sup> Scotland
    </td>
    <td>P &gt; 3 m</td>
    <td>N, P ≤ 3 months</td>
    <td/>
    <td/>
    <td>Yes up to 24 h post-antibiotics</td>
   </tr>
   <tr>
    <td> IDSA USA/Global</td>
    <td>P, A</td>
    <td>N, A &gt; 50 years</td>
    <td>N</td>
    <td>P, A</td>
    <td>P
     <sup>^</sup>, infants if Hib, A
    </td>
   </tr>
   <tr>
    <td> AEPED Spain</td>
    <td>P</td>
    <td>N, P ≤ 3 months</td>
    <td/>
    <td>**,
     <sup>^</sup>
    </td>
    <td>Yes</td>
   </tr>
   <tr>
    <td> MSF Global</td>
    <td>P &gt; 3 m, A</td>
    <td>N, P ≤ 3 months</td>
    <td>N, P ≤ 3 months</td>
    <td/>
    <td>Yes
     <sup>^</sup>
    </td>
   </tr>
   <tr>
    <td> NNF Norway</td>
    <td>NS</td>
    <td>NS</td>
    <td/>
    <td/>
    <td>Yes</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>The table shows empirical treatment recommendations for different risk groups</p>
  <p>*Initial recommendations to be reviewed as appropriate pending diagnostic results</p>
  <p>**If suspicion of reduced sensitivity to penicillin</p>
  <p>
   <sup>^</sup>Not to neonates
  </p>
  <p>
   <sup>^^</sup>Not to infants &lt; 3 months
  </p>
  <p>
   <sup>″</sup>Not to immunosuppressed
  </p>
  <p>
   <sup>#</sup>Focused on 
   <italic>N. meningitidis</italic> only
  </p>
  <p>
   <italic>Abbreviations</italic>: 
   <italic>N</italic> neonate, 
   <italic>P</italic> paediatric populations, 
   <italic>A</italic> adults, 
   <italic>E</italic> elderly, 
   <italic>NS</italic> non-specified population
   <italic>, EFNS</italic> European Federation of Neurological Societies, 
   <italic>ESCMID</italic> European Society of Clinical Microbiology and Infectious Diseases, 
   <italic>DSI</italic> Dansk Selskab for Infektionsmedicin, 
   <italic>SPILF</italic> Société de Pathologie Infectieuse de Langue Française, 
   <italic>DGN</italic> Deutsche Gesellschaft für Neurologie, 
   <italic>BM</italic> Bakterielle Meningoenzephalitis, 
   <italic>HPSC</italic> Health Protection Surveillance Centre, 
   <italic>NVN</italic> Nederlandse Vereniging voor Neurologie, 
   <italic>MHSSE</italic> Ministry of Health, Social Services and Equality, 
   <italic>NICE</italic> The National Institute for Health and Care Excellence, 
   <italic>UKJSS</italic> UK Joint Specialist Societies, 
   <italic>SIGN</italic> Scottish Intercollegiate Guidelines Network, 
   <italic>IDSA</italic> Infectious Diseases Society of America, 
   <italic>AEPED</italic> Asociación Española de Pediatría, 
   <italic>MSF</italic> Médecins Sans Frontières, 
   <italic>NNF</italic> Norsk Nevrologisk Forening
  </p>
 </table-wrap-foot>
</table-wrap>
